⌕
Corcept Therapeutics · CORT · Nasdaq
Tenet 54 · Mixed
Compare
$70.07+1.23%At closeTenet 54 · Mixed
$70.07+0.85 (+1.23%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Corcept Therapeutics (CORT) Stock Checks

How CORT measures up against value, income, timing, and long-hold tenets. Every criterion shows the number as of the last close and the pass rule. Always free.

Sources Company filings and computed by Tenet Filings and TenetScreens as of How we compute thisNot investment advice

The tenets below and the 0-100 Tenet Score on this report are two separate computations: each tenet runs its own criteria and its own pass rule, while the score is a percentile composite reported as one of four verdict words (Strong, Solid, Mixed or Weak).

3 / 17 qualify todayas of close, Nov 16, 2026 · computed nightly from our fundamentals DB; point-in-time auditable.
QUALIFIES
3
meet every gate today
BORDERLINE
3
within one input of the gate
FAILS
8
miss at least one gate
UNKNOWN
3
insufficient data to judge
Buffett Qualitydurable moat
✓ Qualifies
PassesROE ≥ 15%22.1% · ≥ 15.0%
PassesGross margin ≥ 40%98.5% · ≥ 40.0%
PassesNet margin ≥ 15%16.8% · ≥ 15.0%
PassesDebt/equity ≤ 0.50.00 · ≤ 0.50
FailsGrowing FCF (multi-yr)−1.2% · > 0
Decided by the pass rule for Buffett Quality.
The badge above reads a pass with 1 of the checks below marked as failing. The pass rule for Buffett Quality is what decides that verdict, and it is not restated here.Buffett Quality under The screens ›Today's Buffett Quality list ›
PassesReturn on assets positive11.9% · > 0
PassesOperating cash flow positive$142.0M · > 0
FailsReturn on assets improving16.8% → 11.9%
PassesEarnings backed by cash (CFO > net income)$142.0M vs $99.7M
FailsLeverage falling (long-term debt / assets)We hold no record of long-term debt as a share of assets for both years for this company, so this signal could not be measured. It still scores 0 under this module's conservative rule (a point is never awarded without evidence), and it is not counted as one of the signals we were able to measure.no
FailsCurrent ratio improving3.35 → 2.92
FailsNo share dilution (≤ +2%)+5.7%
FailsGross margin expanding98.4% → 98.3%
PassesAsset turnover improving0.80 → 0.91
Decided by the pass rule for Piotroski F-Score.
The pass rule for Piotroski F-Score is what decides that verdict, and it is not restated here. 1 of 9 carry no data.Piotroski F-Score under The screens ›Today's Piotroski F-Score list ›
FailsROIC ≥ 15%13.3% · ≥ 15.0%
PassesNet debt/EBITDA ≤ 3×−3.4× · ≤ 3.0×
PassesAltman Z ≥ 3 (safe zone)25.45 · ≥ 3.00
Decided by the pass rule for Munger Compounders.
The pass rule for Munger Compounders is what decides that verdict, and it is not restated here.Munger Compounders under The screens ›Today's Munger Compounders list ›
PassesEBIT > 0$110.9M · > 0
FailsEarnings yield EBIT/EV ≥ 6%1.5% · ≥ 6.0%
PassesReturn on capital ≥ 25%30.7% · ≥ 25.0%
Decided by the pass rule for Magic Formula.
The pass rule for Magic Formula is what decides that verdict, and it is not published separately on the methodology page.About this screen ›Today's Magic Formula® list ›
PassesSize: market cap ≥ $2B$7.6B · ≥ $2.0B
PassesCurrent ratio ≥ 23.00 · ≥ 2.00
PassesPositive EPS 10y10y
FailsPays a dividend$0.00 · > 0
FailsEPS growth ≥ 3%/yr−0.8% · ≥ 3.0%
FailsP/E ≤ 1553.52 · ≤ 15.00
FailsP/E × P/B ≤ 22.5486.30 · ≤ 22.50
Decided by the pass rule for Graham Defensive.
The pass rule for Graham Defensive is what decides that verdict, and it is not restated here.Graham Defensive under The screens ›Today's Graham Defensive list ›
Unknown — no dataPEG < 1 (hist. growth)— · < 1.00
FailsEPS growth 10–30%−0.8% · 10.0%–30.0%
Verdict Unknown for this set.
Verdict Unknown for this set. 1 of 2 checks below carry data.Lynch GARP under The screens ›Today's Lynch GARP list ›
FailsPays a dividend$0.00 · > 0
Unknown — no dataYield in a healthy band (not a yield trap)0.0% · 1.0%–8.0%
Unknown — no dataCovered by free cash flow— · ≥ 1.20
Unknown — no dataEarnings payout not stretched— · ≤ 75.0%
Unknown — no dataBalance sheet can sustain the payout−3.4× · ≤ 4.0×
Verdict Unknown for this set.
Verdict Unknown for this set. 1 of 5 checks below carry data. The pass rule for Income & Dividend Safety is not published separately on the methodology page.
FailsPays a dividend$0.00 · > 0
Unknown — no dataAnnual dividend raised 10+ years running (Aristocrat ≥25, King ≥50)— · ≥ 10.00
Unknown — no dataNo dividend cut in the last 5 years—
Unknown — no data5-year dividend growth ≥ 5%/yr— · ≥ 5.0%
Unknown — no dataCovered by free cash flow— · ≥ 1.20
Unknown — no dataPayout not stretched— · ≤ 75.0%
Verdict Unknown for this set.
Verdict Unknown for this set. 1 of 6 checks below carry data.Dividend Growth under The screens ›Today's Dividend Growth list ›
PassesReturn on invested capital ≥ 15% in 4+ of the last 5 years4 of 5
PassesRevenue compounding ≥ 8%/yr over 5 years16.6% · ≥ 8.0%
PassesNot diluting: diluted share count flat-to-down (≤ +1%/yr)−0.4% · ≤ 1.0%
PassesFree cash flow margin ≥ 12%20.2% · ≥ 12.0%
PassesEarnings backed by cash (operating cash flow ≥ net income)1.22 · ≥ 1.00
Reading: holds. Not a gate checkDisciplined buybacks: actively reducing the share count (bonus)reading, not a gate check−0.4%
Decided by the pass rule for Quality Compounder.
The pass rule for Quality Compounder is what decides that verdict, and it is not restated here. Lines marked as readings are published beside the checks and are not gate checks.Quality Compounder under The screens ›Today's Quality Compounder list ›
FailsOff its 52-week high by 8–35% (a dip, not a collapse)45.2% · 8.0%–35.0%
FailsDip within its own normal pullback band0.44
FailsNot past where its dips have historically recovered from4.50
FailsA dip in an uptrend (above a rising 200-day)76.64
FailsHigher-low structure still intactstructure broken · higher low
Unknown — no dataClear of the earnings blackout (more than 5 days out)— · > 5.00
Decided by the pass rule for Drawdown Context.
The pass rule for Drawdown Context is what decides that verdict, and it is not published separately on the methodology page. 1 of 6 carry no data.
Unknown — no dataA bullish MACD cross within 10 sessions— · ≤ 10.00
FailsReclaimed a rising 50-day EMA95.19
PassesPrinted a higher lowyes
FailsA volume thrust on the turn (≥ 1.2× normal)1.06 · ≥ 1.20
FailsReversal signals fired: 3 of 4 (MACD·MA·HL·Vol)1.00 · ≥ 3.00
Decided by the pass rule for Reversal Evidence.
The pass rule for Reversal Evidence is what decides that verdict, and it is not published separately on the methodology page. 1 of 5 carry no data.
FailsIn the cheap half of its own 5-year valuation range1.0×
PassesEarnings estimates not being cut0.12
FailsReturns on capital not deteriorating0.07
Decided by the pass rule for Not-a-Value-Trap Gate.
The pass rule for Not-a-Value-Trap Gate is what decides that verdict, and it is not published separately on the methodology page.
PassesOperating profit is positive$110.9M · > 0
PassesReturn on invested capital ≥ 10%13.3% · ≥ 10.0%
PassesA solvent balance sheet (Altman Z ≥ 1.8, net debt/EBITDA ≤ 4)25.5×
PassesQuality score ≥ 5071.40 · ≥ 50.00
PassesRevenue growing over 5 years16.6% · > 0
Decided by the pass rule for Quality Floor.
The pass rule for Quality Floor is what decides that verdict, and it is not published separately on the methodology page.
A research signal from published criteria, not a recommendation.
FailsDrawdown context45.2% off its 52-week high
FailsReversal evidence1 of 4 signals fired
FailsTrap gate1 of 3 held
PassesQuality floor5 of 5 held
Invalidation level (structure break): below this the dip's structure has broken$110.29
Decided by the pass rule for Qualified Dip.
The pass rule for Qualified Dip is what decides that verdict, and it is not restated here.Qualified Dip under The screens ›Today's Qualified Dip list ›
FailsTrading above its 50-day average102.85
FailsTrading above its 200-day average76.64
Passes50-day average above the 200-day (uptrend stack)102.85
Fails50-day average sloping up−0.11 · > 0
Decided by the pass rule for Trend Alignment.
The pass rule for Trend Alignment is what decides that verdict, and it is not published separately on the methodology page.
Fails3-month return in the top half of the universe0.05 · ≥ 0.50
Passes12-minus-1 momentum in the top half of the universe0.83 · ≥ 0.50
FailsRelative strength vs the S&P 500 improving−0.01 · > 0
PassesEarnings estimates being revised up0.12
Decided by the pass rule for Relative Strength.
The pass rule for Relative Strength is what decides that verdict, and it is not published separately on the methodology page.
FailsMACD above its signal line−9.93
Not scored: see the reason belowBack above the 50-day on a fresh cross (≤10 sessions)This is a two-part reading (price back above the 50-day, and a bullish momentum cross inside 10 sessions) and a dated momentum cross is not on record for this name yet, so it is left unscored rather than counted either way.—
FailsHigher high and higher low (stair-stepping up)no higher high · higher low
FailsA volume thrust on the move (≥ 1.2× normal)1.06 · ≥ 1.20
Decided by the pass rule for Momentum Trigger.
The pass rule for Momentum Trigger is what decides that verdict, and it is not published separately on the methodology page. 1 of 4 carry no data.
Average daily swing: high0.08
Volatility band width: expanded (wide range)0.90
Distance from its 52-week high: a deep pullback0.45
Every verdict is auditableEach criterion shows the number as of the last close and the pass rule side by side: a receipt, not a rating. Several of these screens publish their rule in full under The screens; each row links to its own section where there is one.
Unknown ≠ failAn “— Unknown” verdict means the inputs were insufficient: context, not a signal, and never counted as a fail.

How many investing rule sets does Corcept Therapeutics pass?

Corcept Therapeutics qualifies on 3 of 17 rule sets as of 2026-11-16, with 3 borderline and 8 failing.

Does Corcept Therapeutics meet the Graham Defensive criteria?

Corcept Therapeutics fails the Graham Defensive rule set as of 2026-11-16.

Does Corcept Therapeutics meet the Buffett Quality criteria?

Corcept Therapeutics qualifies on the Buffett Quality rule set as of 2026-11-16.

Computed from our fundamentals DB; historical-CAGR PEG basis for Lynch. Research, not investment advice. Tenet's rulesets are independently developed from publicly available sources, and Tenet is not affiliated with, sponsored by, endorsed by or otherwise associated with any referenced investor or trademark owner. Full notice. MAGIC FORMULA is a trademark of MagicFormulaInvesting.com LLC.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.